***Background.*** The objective of this work was to assess the social pattern of serogroup B invasive meningococcal disease (IMD-B) incidence and outcomes in the province of Quebec, Canada.

***Methods.*** Medical records of laboratory confirmed cases of IMD-B between 1997 and 2010 in the province of Quebec were reviewed through a standardized questionnaire. Social and material deprivation index within the Province of Quebec, by quintile, was assigned to each patient according to postal code of residence. The incidence of IMD-B according to social and material deprivation index was calculated, and the effect of deprivation on the risks of acute complication, major sequelae in survivors and fatal outcome were assessed using logistic regression.

***Results.*** Over the 14 year period, 571 cases were identified. Deprivation index were assigned for 527 cases. Incidence rate, by quintile of material deprivation, ranged from 0.31 to 0.54/100,000 person-years, with the lowest incidence found for the most affluent quintile and the highest for the most deprived quintile (P \< 0.0001). Among infants \<1 year-old and children 1-14 year-old, incidence rates were respectively 3.5 and 2.5 times higher in the most materially deprived quintile than in the most affluent quintile (P = 0.0002 and P = 0.002 respectively).

The risk of major sequelae rose with level of material deprivation index and the association was statistically significant (OR = 1.20, 95%CI: 1.01 -1.43, P = 0.04). It rose with level of social deprivation index but was not statistically significant (OR = 1.10, 95%CI: 0.93-1.30, P = 0.28). No association with material and social deprivation was found for acute complication and fatal outcome.

***Conclusion.*** In the Province of Quebec, material deprivation is associated with higher incidence rates of IMD-B and higher risk of major sequelae, but not with risk of acute complication or risk of death. Social deprivation does not seem to play a significant role.
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